Klin Farmakol Farm. 2022;36(4):150-155 | DOI: 10.36290/far.2022.025

Reinitiation of clozapine treatment

Michaela Mayerová1, Libor Ustohal1, 2
1 Psychiatrická klinika, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity, Brno
2 Ústav farmakologie a toxikologie, Farmaceutická fakulta Masarykovy univerzity, Brno

The article deals with the reinitiation of clozapine treatment after it was discontinued for a reason (mostly because of side effects). Reinitiation is a controversial topic, especially after severe to life-threatening side effects. When is the reiniation possible and how should this be done? We try to provide a summary of relevant information which is available in literature of recent years or in therapeutic guidelines.

Keywords: clozapine, reinitiation, side effects, myocarditis, agranulocytosis, ileus, schizophrenia.

Accepted: February 8, 2023; Published: February 8, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mayerová M, Ustohal L. Reinitiation of clozapine treatment. Klin Farmakol Farm. 2022;36(4):150-155. doi: 10.36290/far.2022.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. The American Journal Of Psychiatry. 1999;156(7):990-999. Go to original source... Go to PubMed...
    2. Leucht S, Corves C, Arbter D, et al. Articles: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet. 2009;373:31-41. Go to original source... Go to PubMed...
    3. Leucht S, Cipriani A, Spineli L, et al. Articles: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet. 2013;382:951-962. Go to original source... Go to PubMed...
    4. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v first- and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis. The British Journal of Psychiatry. 2016;209(5):385-392. Go to original source... Go to PubMed...
    5. Masuda T, Misawa F, Takase M, et al. Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. JAMA Psychiatry. July 2019. Go to original source... Go to PubMed...
    6. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet. 2019;394(10202):939-951. Go to original source... Go to PubMed...
    7. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clinical Schizophrenia & Related Psychoses. 2012;6(3):134-144. Go to original source... Go to PubMed...
    8. Siskind D, Siskind V, Kisely S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Canadian Journal Of Psychiatry Revue Canadienne De Psychiatrie. 2017;62(11):772-777. Go to original source... Go to PubMed...
    9. Schulte P. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clinical Pharmacokinetics. 2003;42(7):607-618. Go to original source... Go to PubMed...
    10. Leponex. Souhrn údajů o přípravku, datum revize textu 25.8.2022. [online]. http://www.sukl.cz/modules/medication/detail.php?code=0235103&tab=texts
    11. Horvitz-Lennon M, Donohue JM, Lave JR, et al. The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries. Psychiatric Services (Washington, DC). 2013;64(3):230-237. Go to original source... Go to PubMed...
    12. Haro JM, Novick D, Belger M, Jones PB. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. European Psychiatry. 2006;21(1):41-47. Go to original source... Go to PubMed...
    13. Waserman J, Criollo M. Subjective experiences of clozapine treatment by patients with chronic schizophrenia. Psychiatric Services (Washington, DC). 2000;51(5):666-668. Go to original source... Go to PubMed...
    14. Angermeyer MC, Löffler W, Müller P, et al. Patients' and relatives' assessment of clozapine treatment. Psychological Medicine. 2001;31(3):509. Go to original source... Go to PubMed...
    15. Mustafa FA, Burke JG, Abukmeil SS, et al. "Schizophrenia past Clozapine": Reasons for Clozapine Discontinuation, Mortality, and Alternative Antipsychotic Prescribing. Pharmacopsychiatry. 2015;48(1):11. Go to original source... Go to PubMed...
    16. Davis MC, Fuller MA, Strauss ME, et al. Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. Acta Psychiatrica Scandinavica. 2014;130(1):30-39. Go to original source... Go to PubMed...
    17. Pai NB, Vella SC. Reason for clozapine cessation. Acta Psychiatrica Scandinavica. 2012;125(1):39-44. Go to original source... Go to PubMed...
    18. Legge SE, Hamshere M, Hayes RD, et al. Reasons for discontinuing clozapine: A cohort study of patients commencing treatment. Schizophrenia Research. 2016;174(1-3):113-119. Go to original source... Go to PubMed...
    19. Stahl SM. Antipsychotic agents. In: Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 4th Ed. 2013. https://doctorlib.info/pharmacology/stahls-essential-psychopharmacology-4/5.html
    20. Rubio JM, Kane JM. How and when to use clozapine. Acta Psychiatrica Scandinavica. October 2019. Go to original source...
    21. Blackman G, Oloyede E, Horowitz M, et al. Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation-Is It Feasible to Develop Evidence-Based Guidelines? Schizophrenia Bulletin. 2022;48(1):176-189. Go to original source... Go to PubMed...
    22. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th ed. West Sussex, United Kingdom: John Wiley & Sons 2021. Go to original source...
    23. Correll CU, Agid O, Crespo-Facorro B, et al. A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS Drugs. 2022;36(7):659-679. Go to original source... Go to PubMed...
    24. Luykx JJ, Stam N, Tanskanen A, Tiihonen J, Taipale H. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. The British journal of psychiatry : the journal of mental science. 2020;217(3):498-505. Go to original source... Go to PubMed...
    25. Stam N, Taipale H, Tanskanen A, et al. Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics. CTS: Clinical & Translational Science. 2020;13(6):1170-1177. Go to original source... Go to PubMed...
    26. John AP, Burrows S, Stanley S, et al. Demographic and clinical characteristics of patients who recommence clozapine following therapy interruptions. Acta Psychiatrica Scandinavica. 2022;145(3):293-300. Go to original source... Go to PubMed...
    27. What should be done if the clozapine treatment of a patient is interrupted, or they do not take their clozapine for a few days or longer? SMI advisor. A clinical support system for serious mental illness. American Psychiatric Asscociation. 2020.
    28. Manu P, Lapitskaya Y, Shaikh A, Nielsen J. Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases. American Journal of Therapeutics. 2018;25(2):E218-E223. Go to original source... Go to PubMed...
    29. West S, Rowbotham D, Xiong G, Kenedi C. Clozapine induced gastrointestinal hypomotility: A potentially life threatening adverse event. A review of the literature. General Hospital Psychiatry. 2017;46:32-37. Go to original source... Go to PubMed...
    30. Every-Palmer S, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: An analysis of 102 cases. The Journal of Clinical Psychiatry. 2008;69(5):759-768. Go to original source... Go to PubMed...
    31. Richardson N, Greenway SC, Bousman CA. Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review. Psychiatry Research. 2021;305. Go to original source... Go to PubMed...
    32. Masopust J, Kopeček M, Protopopová D. Sledování tělesného zdraví u pacientů se závažnými neorganickými duševními poruchami (psychózy, bipolární porucha, depresivní porucha). Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. 2020. https://postupy-pece.psychiatrie.cz/obecna-psychiatrie/sledovani-telesneho-zdravi
    33. Ronaldson KJ, Fitzgerald PB, Taylor AJ et al: A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Australian & New Zealand Psychiatry. 2011; 45(6): 458-65. Go to original source... Go to PubMed...
    34. Bellissima BL, Tingle MD, Cicović A et al: A systematic review of clozapine induced myocarditis. International Journal of Cardiology. 2018; 259: 122-29. Go to original source... Go to PubMed...
    35. Vickers M, Ramineni V, Malacova E, et al. Risk factors for clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica. 2022;145(5):442-455. Go to original source... Go to PubMed...
    36. Hosseini SA, Skrzypcak B, Yasaei R, et al. Successful Clozapine Re-Challenge After Suspected Clozapine-Induced Myocarditis. American Journal of Case Reports. 2020;21:1-6. Go to original source... Go to PubMed...
    37. Noël M-C, Powell V, Burton L et al: Clozapine-related myocarditis and rechallenge: A case series and clinical review. Journal of Clinical Psychopharmacology. 2019; 39(4): 380-85 Go to original source... Go to PubMed...
    38. Ronaldson KJ, Fitzgerald PB, Taylor AJ et al: Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: A case-control study. Schizophrenia Research. 2012; 141(2-3): 173-78. Go to original source... Go to PubMed...
    39. de Leon J, Tang Y-L, Baptista T, et al. Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations. Acta Psychiatrica Scandinavica. 2015;132(4):242-243. Go to original source... Go to PubMed...
    40. Griffin JM, Woznica E, Gilotra NA, Nucifora FC Jr. Clozapine-Associated Myocarditis: A Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to Conduct a Clozapine Rechallenge. Journal of Clinical Psychopharmacology. 2021;41(2):180-185. Go to original source... Go to PubMed...
    41. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):e1. Go to original source... Go to PubMed...
    42. Hefner G, Shams M, Unterecker S, Falter T, Hiemke C. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. Psychopharmacology. 2016;233(9):1695-1705. Go to original source... Go to PubMed...
    43. Whiskey E, Taylor D. Restarting clozapine after neutropenia : Evaluating the possibilities and practicalities. CNS drugs. 2007;21(1):25-35. Go to original source... Go to PubMed...
    44. Malik S, Lally J, Ajnakina O, et al. Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophrenia Research. 2018;195:267-273. Go to original source... Go to PubMed...
    45. Myles N, Myles H, Clark SR, et al. Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations. Australian and New Zealand Journal of Psychiatry. 2017;51(10):980-989. Go to original source... Go to PubMed...
    46. Lally J, Malik S, Krivoy A, Whiskey E, Taylor DM, Gaughran FP, Flanagan RJ, Mijovic A, MacCabe JH. The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review. Journal of Clinical Psychopharmacology. 2017;37(5):600-604. Go to original source... Go to PubMed...
    47. Lichnovský O, Ustohal L. Vysazení klozapinu z důvodu neutropenie a možnosti jeho opětovného nasazení do medikace. Psychiatrie. 2022;4:167-171.
    48. Yadav D, Burton S, Sehgal C. Clozapine-induced neutropenia reversed by lithium. Progress in Neurology & Psychiatry. 2016;20(3):13-15. Go to original source...
    49. Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. The Journal of Clinical Psychiatry. 2006;67(5):756-760. Go to original source... Go to PubMed...
    50. Kourti, K. Paschalidis, C-M. Platsa, et al. Clozapine Rechallenge with Lithium After Double Induced Neutropenia: A Case Report. Dialogues in Clinical Neuroscience & Mental Health. 2019;1(4):150-157.
    51. Carmen J, Okafor K, Ike E. The effects of lithium therapy on leukocytes: a 1-year follow-up study. Journal of the National Medical Association. 1993;85(4):301-303. Go to PubMed...
    52. Clozapine treatment guidelines https://www.candi.nhs.uk/sites/default/files/Clozapine%20Treatment%20guidelines%20_PHA06_August%202021.pdf
    53. Boazak M, Goldsmith DR, Cotes RO. Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be Risky. The Primary Care Companion for CNS disorders. 2018;20(6). Go to original source... Go to PubMed...
    54. Béchard L, Morasse-Bégis M, Corbeil O, et al. Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series. Journal of Clinical Psychopharmacology. May 2022. Go to original source... Go to PubMed...
    55. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. The British Journal of Psychiatry : the journal of mental science. 2006;188:255-263. Go to original source... Go to PubMed...
    56. Shuman M, Dilich A, Moss L. Never Say Never: Successful Clozapine Rechallenge After Multiple Episodes of Neutropenia. FOCUS. 2021;19:66-70. Go to original source... Go to PubMed...
    57. Oloyede E, Blackman G, Whiskey E, et al. Clozapine haematological monitoring for neutropenia: a global perspective. Epidemiology and Psychiatric Sciences. 2022;31:e83. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.